Israel - Ibrani - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate 125 mg / 5 ml; clavulanic acid as potassium 31.25 mg / 5 ml - suspension - ampicillin and enzyme inhibitor - fot the treatment of lower respiratory tract infections, otitis media infections, sinusitis infections, acute pharyngitis, skin and soft tissues infections and urinary tract infections caused also by beta-lactamase producing organisms which are susceptible to augmentin and are resistant to other beta-lactam antibiotics.

Israel - Ibrani - Ministry of Health

promedico ltd - barium sulfate 80.9977 %w/w - suspension - barium sulfate with suspending agents - radiolography of the gastro-intestinal tract. for use in x-ray departments.

Israel - Ibrani - Ministry of Health

intervet ( israel) ltd - cefquinome as sulfate 25 mg/ml - suspension for injection - for the treatment of infections diseases caused by microorganisms susceptible to cefquinome in cattle and pigs.

Israel - Ibrani - Ministry of Health

comex ltd - procaine benzylpenicillin 300 mg/ml - suspension for injection - norocillin is recommended in the treatment of diseases caused by susceptible organisms to penicillin in cattle, sheep and pigs.

Israel - Ibrani - Ministry of Health

euromar ltd - diclazuril 2.5 mg/ml - suspension - for the prevention of coccidiosis due to eimeria crandalis and eimeria ovinoidalis in lambs. prevention of coccidiosis due to eimeria bovis and eimeria zuernii in calves.

Israel - Ibrani - Ministry of Health

glaxo smith kline (israel) ltd - a/california/7/2009 (h1n1) 15 mcg / 0.5 ml; a/victoria/361/2011 (h3n2) 15 mcg / 0.5 ml - suspension for injection - influenza, live attenuated - prophylaxis of influenza, especially those who run an increased risk of associated complications. fluarix is indicated in adults and children from 6 months of age.

Israel - Ibrani - Ministry of Health

medici ltd - diphtheria toxoid 2 iu / 0.5 ml; poliomyelitis virus type 1 40 du/dose - suspension for injection - diphtheria-poliomyelitis-tetanus - this combined vaccine is indicated for adults as a booster of a previous vaccination for the simultaneous prevention of diphtheria tetanus and poliomyelitis. refer to the official recommendations for vaccination schedules. this vaccine may be administered as a booster of a previous vaccination to children 6 or older in exceptional cases particularly in the case of a shortage of the diphtheria tetanus and poliovirus vaccine (dtpolio) recommended in the vaccination schedule.

Israel - Ibrani - Ministry of Health

comex ltd - sulphadiazine 2.5 %w/v; trimethoprim 0.5 %w/v - suspension - intrammamary suspension for the broad spectrum treatment of clinical mastitis in the lactating cow.

Israel - Ibrani - Ministry of Health

merck sharp & dohme israel ltd - protein l1 (type 11) 40 mcg / 0.5 ml; protein l1 (type 16) 40 mcg / 0.5 ml - suspension for injection - gardasil is indicated in females aged 9 through 45 years* for the prevention of cervical, vulvar, vaginal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, and 18 (which are included in the vaccine). gardasil is indicated in males 9 through 26 years* of age for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infection caused by hpv types 6, 11, 16, and 18 (which are included in the vaccine). *immunogenicity studies have been conducted to link efficacy in females and males aged 16 to 26 years to the younger populations.

Israel - Ibrani - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - rotavirus g1 reassortant; rotavirus g2 reassortant; rotavirus g3 reassortant; rotavirus g4 reassortant; rotavirus p1a[8] reassortant - suspension - rotavirus p1a[8] reassortant 2.3 x10 ^6 iu/dose; rotavirus g2 reassortant 2.8 x10 ^6 iu/dose; rotavirus g4 reassortant 2.0 x10^ 6 iu/dose; rotavirus g3 reassortant 2.2 x10 ^6 iu/dose; rotavirus g1 reassortant 2.2 x10 ^6 iu/dose - rota virus diarrhea vaccines - rotateq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes g1, g2, g3, and g4 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. the first dose of rorateq should be administered betwen 6 and 12 weeks of age.